Theravance Biopharma (TBPH) Misses Q1 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Theravance Biopharma, Inc. Reports First Quarter 2016 Financial Results and Provides Business Update
May 9, 2016 4:15 PM EDTDUBLIN, IRELAND -- (Marketwired) -- 05/09/16 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today reported financial results for the first quarter ended March 31, 2016. Revenue for the first quarter 2016 was $18.4 million. The first quarter operating loss excluding share-based compensation was $30.3 million, or $41.6 million including share-based compensation of $11.3 million. Cash, cash equivalents, and marketable securities totaled $214.5 million as of March 31, 2016. The quarter-end cash balance excludes $37.5 million in receivables from collaborative arrangements and approximately $107.7 million in net proceeds from the Company's recent public offering of its ordinary shares.
Rick E Winningham, Chairman and... More
